CD4 News and Research

RSS

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) or lopinavir (LPV) and ritonavir (LPV/r) were effective in suppressing HIV in patients who had failed prior PI-containing regimens, according to information presented at the International AIDS Conference (IAC).

12 Jul 2004

A new protocol for bone marrow transplants

A new protocol for bone marrow transplants, which does not require the destruction of the recipient’s immune system before transfer of the new bone marrow, is described by a group of Oxford scientists

5 Jul 2004

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

The development of simple and inexpensive generic fixed-dose combined therapies appears the most suitable solution for making possible this access to treatments in developing countries with meagre resources.

3 Jul 2004

Generic fixed-dose combinations (FDCs) of antiretrovirals are a key factor in access to treatment of HIV/AIDS infection in the developing world

Combination therapy with three generic antiretroviral drugs in a single tablet has been validated for the first time in an open clinical study in a developing country. Follow-up of 60 patients treated in Yaoundé, Cameroon, has demonstrated the excellent efficacy and safety of a generic fixed-dose combination.

2 Jul 2004

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

One of the strategies adopted consists in utilizing combinations of fixed doses of generic antiretrovirals, involving three medicinal drugs of two different classes in the same tablet.

2 Jul 2004

Women delay AIDS with vitamins B, C and E

Daily intake of multivitamins appears to delay the progress of the AIDS virus according to the results of a study of HIV infected women in Tanzania by Harvard researchers.

30 Jun 2004

Discovery may explain why people with AIDS may suffer severe infections from viruses that they would otherwise defeat

Researchers have uncovered the first evidence that a virus can mutate to evade the body's first line of immune defense.

25 Jun 2004

Hair cloning could be the cure for baldness

Researcher Kevin McElwee -- one of only a few people in the world who hold a doctoral degree in hair biology -- thinks a cure for baldness that uses the technique of hair cloning could be commercially available within 10 years.

24 Jun 2004

Mothers infected with HIV who breast feed risk infecting infants

After four weeks of age, infants who breast feed from mothers infected with HIV continue to be at risk for infection with HIV for as long as they breastfeed

17 Jun 2004

Possible new second-generation multiple sclerosis therapy

Scientists from Genencor International, Inc., have demonstrated in an in vivo model that a new variant of recombinant interferon-beta reduces the immunological response to the protein.

25 May 2004

Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

24 May 2004

Weekly cycles of once-daily anti-drugs could reduce cost of HIV treatment

In a small study conducted at the U.S. National Institutes of Health (NIH), researchers have shown that it may be feasible to treat HIV-infected patients with a simple, once-daily regimen of anti-HIV drugs given in pre-planned, 7-day-on, 7-day-off cycles. This approach is known formally as “short-cycle structured intermittent antiretroviral therapy” (SIT) or colloquially as the “7-7” approach.

20 May 2004

Guidelines for FUZEON (enfuvirtide) are published today in AIDS

New international consensus guidelines for FUZEON (enfuvirtide) are published today in AIDS, the official journal of the International AIDS Society.

17 May 2004

Trial of antibody for HIV Infection

Tanox, Inc. announced today that it has begun dosing patients in its Phase 2 clinical trial of TNX-355 for the treatment of the human immunodeficiency virus (HIV).

5 May 2004

Experimental immune-boosting drug interleukin-2 helps HIV Patients

National Institutes of Health (NIH) scientists report that brief, widely-spaced courses of the experimental immune-boosting drug interleukin-2 (IL-2) allow people with HIV to maintain near normal levels of a key immune system cell for long periods.

26 Apr 2004

Cancer-specific protein offers new target for the development of melanoma vaccine

Scientists from the Cancer Vaccine Collaborative (CVC) have discovered that the cancer-specific protein, SSX-2, induces a spontaneous immunological reaction against cancer cells in melanoma patients, offering a new target for the development of a therapeutic melanoma vaccine. SSX-2 is the prototype of the SSX family, and is part of a larger group of proteins known as cancer/testis (CT) antigens.

16 Apr 2004

Trial of new drug that may halt progression of Type I Diabetes

The results of a long-term clinical trial on a new drug designed to inhibit the progression of type I diabetes was announced at the International Diabetes Society meeting in Cambridge, England, March 29. The findings of the 18-month long clinical trial confirm the drug's efficacy in improving a diabetic's ability to produce insulin.

30 Mar 2004

New Cell Sorter Helps Understand Deadly Diseases

Researchers at NC State’s College of Veterinary Medicine have a new state-of-the-art tool, a high-speed cell sorter, that should quicken the pace of their research. The machine sorts or collates cells into groups, allowing scientists to look only at the cells they are working on.

23 Mar 2004